Use of anakinra in severe COVID-19: A case report
Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 96(2020), Seite 607-609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giovanni Filocamo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anakinra |
|---|
| doi: |
10.1016/j.ijid.2020.05.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ027709442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027709442 | ||
| 003 | DE-627 | ||
| 005 | 20230501181658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.05.026 |2 doi | |
| 035 | |a (DE-627)DOAJ027709442 | ||
| 035 | |a (DE-599)DOAJc4b967661cf148e784b48c6952d829e9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Giovanni Filocamo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of anakinra in severe COVID-19: A case report |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra). | ||
| 650 | 4 | |a Anakinra | |
| 650 | 4 | |a IL-1 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Biologic | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Davide Mangioni |e verfasserin |4 aut | |
| 700 | 0 | |a Paola Tagliabue |e verfasserin |4 aut | |
| 700 | 0 | |a Stefano Aliberti |e verfasserin |4 aut | |
| 700 | 0 | |a Giorgio Costantino |e verfasserin |4 aut | |
| 700 | 0 | |a Francesca Minoia |e verfasserin |4 aut | |
| 700 | 0 | |a Alessandra Bandera |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 96(2020), Seite 607-609 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2020 |g pages:607-609 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.05.026 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/c4b967661cf148e784b48c6952d829e9 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971220303337 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2020 |h 607-609 | ||